Ignite Creation Date:
2024-05-06 @ 3:28 PM
Last Modification Date:
2024-10-26 @ 1:50 PM
Study NCT ID:
NCT04647890
Status:
COMPLETED
Last Update Posted:
2023-12-20
First Post:
2020-11-16
Brief Title:
Effects of FT011 in Systemic Sclerosis
Sponsor:
Certa Therapeutics
Organization:
Certa Therapeutics
Study Overview
Official Title:
A Phase II Randomised Double Blind Placebo-controlled Study of the Pharmacokinetics Pharmacodynamic Effects and Safety of Oral FT011 in Participants With Diffuse Systemic Sclerosis
Status:
COMPLETED
Status Verified Date:
2023-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
FT011 is an anti-fibrotic drug that is being tested as a treatment for scleroderma This study is being conducted to see what the body does to the drug pharmacokinetics and what the drug does to the body pharmacodynamics
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None